CLL
From the Journals
Ublituximab was safe, highly active in rituximab-pretreated B-cell NHL, CLL
Ublituximab had good safety and antitumor activity in rituximab-relapsed or -refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic...
From the Journals
In CLL, specific mutation is key to ibrutinib resistance
Specific mutations precede relapse in ibrutinib-treated CLL, offering an opportunity to target asymptomatic clonal expression with novel therapies...
Conference Coverage
In active CLL with deletion 17p, consider trial enrollment
NEW YORK – Outside of clinical trials, therapy for early stage chronic lymphocytic leukemia in patients with deletion of the short arm of...
Conference Coverage
Why CLL may go chemo free
NEW YORK – The approach to treating chronic lymphocytic leukemia is evolving, and while chemoimmunotherapy remains a reasonable initial option in...
From the Journals
AML leads percent gains in 5-year survival among leukemias
For 2008-2013, the 5-year relative survival rate for all leukemia was 60.1%, compared with 10% in 1950-1954.
Conference Coverage
Lenalidomide maintenance extended progression-free survival in high-risk CLL
SAN DIEGO - Lenalidomide maintenance may be an option for patients with chronic lymphocytic leukemia at risk of early progression.
Conference Coverage
Ibrutinib continues to wow in CLL/SLL
SAN DIEGO – More than 90% of the first patients with previously untreated chronic lymphocytic leukemia who received ibrutinib in an early study...
Conference Coverage
Lenalidomide improves PFS after 1st and 2nd line CLL therapy
SAN DIEGO – Lenalidomide, a mainstay of maintenance therapy for multiple myeloma, is now making inroads into maintenance therapy following first-...
Conference Coverage
Idelalisib held unlikely to become frontline therapy for CLL
Safety issues with idelalisib, a first-in-class PI3K delta inhibitor, are an important concern in patients with chronic lymphocytic leukemia–...
From the Journals
Targeted therapies predicted to blow out costs for CLL
Economic models indicate the annual cost in the United States of managing chronic lymphocytic leukemia will increase from its current level of $0....
From the Journals
Minimal residual disease status predicts 10-year survival in CLL
Patients who have chronic lymphocytic leukemia and achieve minimal residual disease negativity have a high probability of long-term progression-...